Background: The NORA study is a prospective longitudinal cohort study aiming at investigating treatment in patients with early breast cancer. Here, we present the impact of the St Gallen recommendations on clinical practice. Patients and methods: We compared adjuvant strategies in patients enrolled in 2000-2002 to those in 2003-2004 to verify the impact of the 2003 St Gallen recommendations. Results: The use of aromatase inhibitors (AIs) doubled: 65/629 patients (10.3%) vs 100/458 patients (21.8) (P < 0.0001). Following chemotherapy, AIs were administered in 8.5% of the retrospective cohort and in 15.1% of the prospective one (P < 0.0001). The use of taxanes plus hormones dropped (P = 0.0026), but not when used as single agents. A marked increase was observed in the use of anthracycline-based chemotherapy (46.3% vs 65.2%), mainly three-drug regimens (33.3% vs 46.6%). Conclusion: Our results suggest that the St Gallen recommendations have had a major impact on clinical practice.
Cazzaniga, M., Mustacchi, G., Pronzato, P., De Matteis, A., Di Costanzo, F., Floriani, I., et al. (2007). Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study. ANNALS OF ONCOLOGY, 18(12), 1976-1980 [10.1093/annonc/mdm365].
Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study
Cazzaniga M
;
2007
Abstract
Background: The NORA study is a prospective longitudinal cohort study aiming at investigating treatment in patients with early breast cancer. Here, we present the impact of the St Gallen recommendations on clinical practice. Patients and methods: We compared adjuvant strategies in patients enrolled in 2000-2002 to those in 2003-2004 to verify the impact of the 2003 St Gallen recommendations. Results: The use of aromatase inhibitors (AIs) doubled: 65/629 patients (10.3%) vs 100/458 patients (21.8) (P < 0.0001). Following chemotherapy, AIs were administered in 8.5% of the retrospective cohort and in 15.1% of the prospective one (P < 0.0001). The use of taxanes plus hormones dropped (P = 0.0026), but not when used as single agents. A marked increase was observed in the use of anthracycline-based chemotherapy (46.3% vs 65.2%), mainly three-drug regimens (33.3% vs 46.6%). Conclusion: Our results suggest that the St Gallen recommendations have had a major impact on clinical practice.File | Dimensione | Formato | |
---|---|---|---|
Cazzaniga-2007-Ann Oncol-VoR.pdf
accesso aperto
Descrizione: Original article
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Licenza:
Altro
Dimensione
113.81 kB
Formato
Adobe PDF
|
113.81 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.